Bicara Therapeutics (BCAX) News Today $18.38 -0.94 (-4.87%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Bicara Therapeutics initiated with a Not Rated at Goldman SachsNovember 20 at 11:48 PM | markets.businessinsider.comFirst Turn Management LLC Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX)First Turn Management LLC purchased a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 562,391 shares of the company's stocNovember 19 at 6:08 AM | marketbeat.comCantor Fitzgerald Issues Negative Estimate for BCAX EarningsNovember 19 at 2:51 AM | americanbankingnews.comBicara Therapeutics (NASDAQ:BCAX) Shares Gap Down - Should You Sell?Bicara Therapeutics (NASDAQ:BCAX) Shares Gap Down - Here's WhyNovember 18 at 1:17 PM | marketbeat.comFY2024 EPS Estimates for BCAX Cut by Cantor FitzgeraldBicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Equities researchers at Cantor Fitzgerald decreased their FY2024 earnings estimates for Bicara Therapeutics in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will post earningsNovember 18 at 2:45 AM | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Stock Price Down 6.2% - What's Next?November 17, 2024 | americanbankingnews.comBicara Therapeutics (NASDAQ:BCAX) Shares Down 6.2% - Here's WhyBicara Therapeutics (NASDAQ:BCAX) Stock Price Down 6.2% - Here's What HappenedNovember 15, 2024 | marketbeat.comPromising Prospects for Bicara Therapeutics: Buy Rating Reinforced by Strong Lead Asset and Strategic PositionNovember 13, 2024 | markets.businessinsider.comBicara Therapeutics: Newly Minted Upsized IPO With Positive Early DataNovember 12, 2024 | seekingalpha.comBicara Therapeutics Inc.: Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | finanznachrichten.deBicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comBicara Therapeutics to Present at the Stifel 2024 Healthcare ConferenceNovember 11, 2024 | globenewswire.comAnalysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $43.33November 11, 2024 | americanbankingnews.comBicara Therapeutics initiated with a Buy at Rodman & RenshawNovember 7, 2024 | markets.businessinsider.comBicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from AnalystsBicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has earned a consensus recommendation of "Buy" from the five ratings firms that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages thNovember 6, 2024 | marketbeat.comRODMAN&RENSHAW Upgrades Bicara Therapeutics (NASDAQ:BCAX) to "Strong-Buy"RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a "strong-buy" rating in a research report on Tuesday.November 6, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Coverage Initiated at Rodman & RenshawRodman & Renshaw began coverage on shares of Bicara Therapeutics in a research note on Tuesday. They set a "buy" rating and a $48.00 price target on the stock.November 5, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Trading Up 7.9% - What's Next?Bicara Therapeutics (NASDAQ:BCAX) Trading 7.9% Higher - Time to Buy?October 18, 2024 | marketbeat.comBicara Therapeutics Inc.'s Quiet Period Will End on October 23rd (NASDAQ:BCAX)Bicara Therapeutics' (NASDAQ:BCAX - Get Free Report) quiet period will expire on Wednesday, October 23rd. Bicara Therapeutics had issued 17,500,000 shares in its IPO on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. During the company's quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.October 16, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Sets New 52-Week Low - What's Next?Bicara Therapeutics (NASDAQ:BCAX) Sets New 52-Week Low - Here's WhyOctober 10, 2024 | marketbeat.comBicara Therapeutics Inc. (NASDAQ:BCAX) to Post FY2024 Earnings of ($1.61) Per Share, Cantor Fitzgerald ForecastsBicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Bicara Therapeutics in a note issued to investors on Tuesday, October 8th. Cantor Fitzgerald analyst E. Schmidt expects thatOctober 10, 2024 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Trading Down 3.5% - What's Next?Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 3.5% - Here's WhyOctober 9, 2024 | marketbeat.comLast Week's 3 Biotech IPOs Prompt Huge Insider BuyingSeptember 22, 2024 | 247wallst.comInsider Buying: Bicara Therapeutics Inc. (NASDAQ:BCAX) Director Buys 1,833,000 Shares of StockSeptember 19, 2024 | insidertrades.comInsider Buying: Bicara Therapeutics Inc. (NASDAQ:BCAX) Major Shareholder Purchases 70,000 Shares of StockSeptember 18, 2024 | insidertrades.comBicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional SharesSeptember 16, 2024 | globenewswire.com Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. BCAX Media Mentions By Week BCAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCAX News Sentiment▼-0.060.46▲Average Medical News Sentiment BCAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCAX Articles This Week▼103▲BCAX Articles Average Week Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OGN News Today IBRX News Today IMVT News Today RYTM News Today APLS News Today MLTX News Today AGIO News Today VRNA News Today PTCT News Today DYN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCAX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
